Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | PLK4 | O00444 | 1/20 | 0.55 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.55 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.55 |
| ▸ | CDK1 | P06493 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.55 |
| ▸ | CDK2 | P24941 | 1/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.55 |
| ▸ | CLK2 | P49760 | 1/20 | 0.55 |
| ▸ | GSK3A | P49840 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6397828 | 0.93 | ALDH1A1 (0.56) | ALDH1A1HTTSMN1; SMN2LMNAPLK4 | |
| SCHEMBL27579461 | 0.83 | PLK4 (0.73) | ALDH1A1HTTSMN1; SMN2LMNAPLK4 | |
| SCHEMBL28270221 | 0.82 | HTT (0.81) | ALDH1A1HTTSMN1; SMN2LMNAPLK4 | |
| SCHEMBL4863981 | 0.82 | PLK4 (0.56) | ALDH1A1HTTSMN1; SMN2LMNAPLK4 | |
| Hydrochloric Acid SCHEMBL4860155 | 0.81 | PLK4 (0.55) | ALDH1A1HTTSMN1; SMN2LMNAPLK4 | |
| SCHEMBL5527306 | 0.79 | HRH3 (0.68) | KDM4EMEN1KMT2A | |
| SCHEMBL5735461 | 0.78 | MAPT (0.57) | HTR2CMEN1KMT2A | |
| SCHEMBL4853400 | 0.77 | HTT (0.60) | ALDH1A1HTTSMN1; SMN2HTR2CKDM4E | |
| SCHEMBL16596346 | 0.77 | HTR1A (0.80) | CDK8HTR1AADRA1DADRA1AADRA1B | |
| SCHEMBL7372365 | 0.77 | PABPC1 (0.61) | ALDH1A1HTTSMN1; SMN2LMNAPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7375227-B2 | Quinoline derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-05-20 | — | — | US | disclosed |
| US-7375227-B2 | Quinoline derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-05-20 | — | — | US | disclosed |
| US-7375227-B2 | Quinoline derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-05-20 | — | — | US | disclosed |
| US-20060211707-A1 | Piperazine-alkyl-ureido derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-09-21 | — | — | US | disclosed |
| EP-1631565-A1 | PIPERAZINE-ALKYL-UREIDO DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2006-03-08 | — | — | EP | disclosed |
| EP-1499607-B1 | 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO)-QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-12-07 | — | — | EP | disclosed |
| EP-1379523-B1 | 1,2,3,4-TETRAHYDROISOQUINOLINES DERIVATIVES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2005-07-27 | — | — | EP | disclosed |
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-02-24 | — | — | US | disclosed |
| EP-1499607-A1 | 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO)-QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-01-26 | — | — | EP | disclosed |
| US-20040242564-A1 | 1,2,3,4-tetrahydroisoquinolines derivatives | VELKER JORG (DE) | 2004-12-02 | — | — | US | disclosed |
| WO-2004099179-A1 | PIPERAZINE-ALKYL-UREIDO DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2004-11-18 | — | — | WO | disclosed |
| US-6815451-B2 | 1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-11-09 | — | — | US | disclosed |
| US-20040110744-A1 | 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-06-10 | — | — | US | disclosed |
| WO-2003048154-A1 | 4-(PIPERIDYL- AND PYRROLIDYL-ALKYL-UREIDO) -QUINOLINES AS UROTENSIN II RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242564-A1 | 1,2,3,4-tetrahydroisoquinolines derivatives | ADRA2C, ADRA1D, ADRB3 | ALDH1A1 1364/4885HTT 684/4885SMN1; SMN2 2811/4885 |
| US-20050043535-A1 | 4-(Piperidyl-and pyrrolidyl-alkyl-ureido)-quinolines as urotensin II receptor antagonists | UTS2R, NTSR2, PLAUR | ALDH1A1 2993/4885HTT 681/4885SMN1; SMN2 2452/4885 |
| US-20060211707-A1 | Piperazine-alkyl-ureido derivatives | ADRA2C, UTS2R, ADRB2 | ALDH1A1 2026/4885HTT 502/4885SMN1; SMN2 2314/4885 |
| US-20040110744-A1 | 1 2 3 4 Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists | UTS2R, NTSR2, NTSR1 | ALDH1A1 2575/4885HTT 882/4885SMN1; SMN2 2177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.